Abdera Therapeutics’ Post

#hiring *Head of Clinical Operations (Sr. Director VP)*, San Diego, *United States*, fulltime #jobs #jobseekers #careers #SanDiegojobs #Californiajobs #Administration *Apply*: https://lnkd.in/dXRJjZVz We started Genesis Therapeutics in 2019 with origins in field-leading AI + biophysics research. Since then, we've dramatically accelerated innovation in Machine Learning and molecular simulation technologies for drug discovery, with the goal of providing new treatments for patients with severe diseases. We are a mission-driven group of researchers, engineers, and drug developers. We believe close-knit, interdisciplinary collaboration is crucial for inventing important new technology and rapidly advancing optimal therapies. Genesis Therapeutics is seeking a Head of Clinical Operations to play a key role in delivering high-quality clinical results across multiple programs. The individual in this position will have the unique opportunity to grow and shape the Genesis Therapeutics clinical operation team at a rapidly growing biotechnology company. In addition, this individual will develop a new project team within the clinical organization to ensure Genesis Therapeutics is on the cutting edge of clinical innovation. This position will contribute to Genesis Therapeutics success by leading the clinical operations activities while working closely with other functional area leads at Genesis Therapeutics and third-party CROs and vendors. ResponsibilitiesThis is a high-profile management positionOversee the overall execution of the assigned clinical program(s) with a focus on quality, budget and timelines, including making decisions or recommending operational strategies in support of achieving Phase III clinical program objectivesLeads the strategy and tactics to successfully work with vendors, investigators, and cross-functional departments to develop, implement and deliver clinical studies/programs supporting our Phase 1-III programsChampions, promotes, and supports the development of high-quality, hard-working study teams to deliver outstanding clinical trialsHas broad experience selecting, managing, troubleshooting, and negotiating with CROs and supporting vendorsLeads strategies for patient recruitment and retention in clinical trialsEstablishes performance, quality, business efficiency, and innovation metrics for the clinical teams and vendors in collaboration with Quality and Risk Management; seeks to improve quality across study programs and ensures quality processes are followedMaintains awareness of industry trends and developments to help define the future strategic direction for the clinical programsPrepares and delivers training, both internally and externally, on new objectives or mandates from authorities, and on training associated with the clinical trials (Investigator Meetings, Re-training)Oversees and is accountable for program budgets, staffing, and tim

#hiring *Head of Clinical Operations (Sr. Director VP)*, San Diego, *United States*, fulltime #jobs #jobseekers #careers #SanDiegojobs #Californiajobs #Administration *Apply*: https://lnkd.in/deZBQDwY We started Genesis Therapeutics in 2019 with origins in field-leading AI + biophysics research. Since then, we've dramatically accelerated innovation in Machine Learning and molecular simulation technologies for drug discovery, with the goal of providing new treatments for patients with severe diseases. We are a mission-driven group of researchers, engineers, and drug developers. We believe close-knit, interdisciplinary collaboration is crucial for inventing important new technology and rapidly advancing optimal therapies. Genesis Therapeutics is seeking a Head of Clinical Operations to play a key role in delivering high-quality clinical results across multiple programs. The individual in this position will have the unique opportunity to grow and shape the Genesis Therapeutics clinical operation team at a rapidly growing biotechnology company. In addition, this individual will develop a new project team within the clinical organization to ensure Genesis Therapeutics is on the cutting edge of clinical innovation. This position will contribute to Genesis Therapeutics success by leading the clinical operations activities while working closely with other functional area leads at Genesis Therapeutics and third-party CROs and vendors. ResponsibilitiesThis is a high-profile management positionOversee the overall execution of the assigned clinical program(s) with a focus on quality, budget and timelines, including making decisions or recommending operational strategies in support of achieving Phase III clinical program objectivesLeads the strategy and tactics to successfully work with vendors, investigators, and cross-functional departments to develop, implement and deliver clinical studies/programs supporting our Phase 1-III programsChampions, promotes, and supports the development of high-quality, hard-working study teams to deliver outstanding clinical trialsHas broad experience selecting, managing, troubleshooting, and negotiating with CROs and supporting vendorsLeads strategies for patient recruitment and retention in clinical trialsEstablishes performance, quality, business efficiency, and innovation metrics for the clinical teams and vendors in collaboration with Quality and Risk Management; seeks to improve quality across study programs and ensures quality processes are followedMaintains awareness of industry trends and developments to help define the future strategic direction for the clinical programsPrepares and delivers training, both internally and externally, on new objectives or mandates from authorities, and on training associated with the clinical trials (Investigator Meetings, Re-training)Oversees and is accountable for program budgets, staffing, and tim

We are #hiring for a #CBO to support a #biotech company specializing in #ADC platform technologies! 📣 #careers Job Title: Chief Business Officer (CBO) Location: United States (Remote with frequent travel) Company Overview: Our client is an innovative oncology-focused biotechnology company specializing in the development of Antibody-Drug Conjugates (ADCs). Their cutting-edge ADC platform is designed to deliver highly targeted and effective treatments for various cancers, offering new hope to patients and transforming the oncology landscape. Job Summary: We are engaged by our client to identify an accomplished and strategic Chief Business Officer (CBO) to join their executive team. The CBO will lead the licensing and business development efforts for their ADC pipeline in the United States. The ideal candidate will possess extensive experience in oncology, a proven track record in business development, and expertise in licensing and strategic partnerships within the biotechnology and pharmaceutical sectors. Key Responsibilities: Strategic Leadership: Develop and execute the overall business development strategy for the company’s ADC pipeline in the U.S. market. Licensing and Partnerships: Identify, negotiate, and manage licensing opportunities and strategic partnerships to maximize the commercial potential of the oncology assets. Market Analysis: Conduct comprehensive market analysis to identify trends, opportunities, and the competitive landscape within the oncology sector. Deal Structuring: Lead the structuring, negotiation, and execution of licensing agreements, collaborations, and partnerships with pharmaceutical and biotechnology companies. Stakeholder Engagement: Build and maintain strong relationships with key stakeholders, including potential partners, investors, and industry leaders. Regulatory and Compliance: Ensure compliance with U.S. regulatory requirements and industry standards in all business development activities. Team Leadership: Lead and mentor a high-performing business development team to achieve strategic goals and objectives. Qualifications: Education: Advanced degree in life sciences, business, or a related field (PhD, MBA, or equivalent). Experience: Minimum of 10 years of experience in business development, licensing, and strategic partnerships within the oncology sector. Expertise: Deep understanding of ADC technology and oncology therapeutic areas. Track Record: Proven success in negotiating and closing licensing agreements and partnerships with major pharmaceutical and biotechnology companies. Apply Here 👉 https://lnkd.in/es6j5Fex #humanresources #recruiting #recruitment #platformtechnology #technology #engineering #science #lifescience #molecularbiology #business #businessdevelopment #leanstartups #csuite #CEO #antibodydrugconjugate #ADCs #antibodies #proteins #monoclonalantibodies #bioconjugation #Oncology #Cancer

#jobalert 🚨for #antibodydrugconjugate biologist in #Cambridge 🇬🇧 for a Scientist. The focus will be on target validation and translation #pharmacology for the AstraZeneca pipeline. This role is in a great team who do meaningful work. You know the drill 👩💻👨🏽💻😉 #jobopportunity #biologics #discovery #makingmedicines #Research #antibodydrugconjugates

StevenDouglas has placed: 5 SVP's of CMC & Tech Ops 5 VP's of CMC & Tech Ops 5 Senior Directors of CMC 6 Directors of CMC (we are modality/function agnostic) Small molecule, large molecule/biologics/monoclonal antibodies, cell therapy, gene therapy, peptides/oligonucleotides, process development, analytical development & quality control, drug substance, drug product, supply chain 5 Directors of Sales (individual contributors/hunters/new business development) Our success can only follow YOUR success! September and October are historically very busy months for hiring in the biopharma domain - If we can be of assistance please reach out. WhyStevenDouglas? - It's all about YOU - YOU come first - We seek first to understand and our end-game goal/charter/credo is to help YOU far exceed YOUR hopes, wishes, ambitions, goals, and dreams by delivering top 1% talent which enables significant internal stakeholder and exponential external shareholder value! #WorkIsTheAnswer #OurCollarsAreBlue #Speed-OurLast5Placements=LessThan45DaysStartToFinish #CompleteMarketCoverage #100%KnowBeforeYouGo

#hiring Principal Scientist, Small Molecule Assay Development, San Francisco, United States, fulltime #jobs #jobseekers #careers #SanFranciscojobs #Californiajobs #ScienceTechnology Apply: https://lnkd.in/gg4C2S2A Principal Scientist, Small Molecule Assay Development About Rezo Therapeutics Rezo is a different kind of biopharma company. Our mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it. Our Founders and members of the Board are a group of esteemed, world-class scientists from the University of California, San Francisco: Nevan Krogan, Kevan Shokat, Sourav Bandyopadhyay, Natalia Jura, as well as renowned biotech executives George Scangos and Norbert Bischofberger. These leaders bring with them a strong track record of amazing discoveries and scientific breakthroughs, leading to very successful companies and many FDA approved drugs. Capitalizing on our Series A of $78M from top-tier investors, we are leveraging a unique integrated approach, combining capabilities in genetics, proteomics, structural biology and AI to generate deep biological insights and novel therapeutic approaches. Located in San Francisco's vibrant Mission Bay neighborhood, Rezo is in close proximity to UCSF, numerous urban amenities, and outdoor recreational opportunities. We recognize that realizing our mission depends as much on our people as it does on our science and are building a workplace that fosters collaboration, respect, and diversity where contributing to your team's success is valued as highly as individual achievements. If you're passionate about team science and breaking down barriers to progress in drug development, please consider joining us! The Opportunity We are seeking a highly enthusiastic and motivated Principal Scientist to join our Discovery Biology team. This role will be responsible for the design and execution of biochemical and biophysical assays of small molecule protein targets. Becoming a member of this team is an excellent opportunity to join Rezo at an early stage and help build the Discovery Biology function and the company from the ground up. What You'll Do: Establish and implement expression strategies and support reagent generation to enable HTP screening and biophysical characterization of multiple protein targetsDesign and oversee diverse, robust, and reproducible biochemical and biophysical assays across all phases of discovery and developmentExplore and evaluate new technologies related to Protein Sciences, and contribute to long-term activity planningPartner with Platform, Discovery Biology, Chemistry, and other departments to drive drug discovery efforts forwardManage and analyze experimental data, interpret results, and prepare necessary materials fo

Continuing the apparent trend of funding going towards clinical development, Mission Therapeutics have announced more support in the form of $5.2 million from the Michael J. Fox Foundation. Looking at Cambridge's omic and biotech space, there appears to be a lull in roles for R&D teams, with the primary focus being on progressing potential drug candidates in the pipeline. We've seen some major changes in teams across the city, both positive and negative. For the scientists looking for next steps and new roles, this has meant a difficult time finding the right role with fewer opportunities out there and fierce competition. For the teams looking to hire it's meant sifting through countless profiles and navigating interviews to figure out who is the best fit in a sea of similar CVs. So what can we expect in the near future? Once the outcomes of these potential therapies have been decided, the focus will likely shift back to R&D. The successful drugs and projects will see another injection of funding to build out teams to validate the next one, while those that are unsuccessful will have to go back to the drawing board for a fresh start. How do you see things progressing? Do you have high or low expectations for the next quarter in the biotech space? Let's connect to talk about all things Omic!

Stories making headlines today in the biopharma industry: Johnson & Johnson (J&J) has shown swift and strategic action in 2023, acquiring $3 billion in assets via over 50 minor licensing partnerships and deals. These acquisitions, aimed at fortifying its position in the sectors of antibody-drug conjugates and CAR-T therapies, flew well under the radar, with media coverage scarcely matching the volume of transaction made by the healthcare giant. Aside from this, in collaboration with Legend Biotech, J&J is also significantly advancing in the production of Carvykti, a CAR-T therapy set to make waves in 2024. In other medical marvels, an experimental gene therapy by Eli Lilly, called AK-OTOF, has given an 11-year-old boy a chance at restored hearing. This remarkable technique offsets the absence of a gene called otoferlin, responsible for transmitting auditory signals from the ear to the brain. Meanwhile, in legislative news, a cross-party body of lawmakers is tackling the issue of pharma patent thickets, piles of patents for a single product. Their proposed legislation aims to minimize the barriers faced by generics and biosimilars in entering the market. Gilead Sciences has just received approval for its $247 million settlement plan by a California federal judge. This settlement aims to resolve the allegations that Gilead Sciences was wrongfully impeding the entry of generic HIV drugs into the market. Lastly, Turquoise Health has obtained $30 million for the progression of AI-powered healthcare pricing. This ambitious digital transformation expects to make healthcare costs transparent and comparable across different healthcare providers, advancing affordability and accessibility for patients. #pharma #biotech #topstories #biodatastudio

Opportunity

🧬 Here is a round up of the latest developments in the Biotech industry 👇 🌍 Measles cases surge globally in 2023, with Europe and Central Asia hit hardest due to vaccination gaps, leading to thousands of hospitalisations. 🧠 FDA finds no clear link between GLP-1 drugs and suicide risk, but continues to evaluate potential associations. 💰 Johnson & Johnson invests $2 billion in acquiring Ambrx, specializing in next-generation antibody-drug conjugates. 🤝 Merck Group to acquire immuno-oncology firm Harpoon Therapeutics for $700 million, expanding its cancer treatment portfolio. 🤝 Calypso Biotech to be acquired by Novartis for $250 million, bolstering its gastroenterology portfolio. 🤝 Boston Scientific to buy Axonics, Inc. for $3.7 billion, marking a significant expansion in the medical device sector. 🫁 GSK acquires Aiolos Bio for $1 billion, targeting clinical-stage respiratory and inflammatory disease treatments. 🧬 Amgen partners with NVIDIA for AI-driven genetic research, utilizing NVIDIA's DGX SuperPOD platform for advanced data analysis. 🤝 Novartis acquires Chinese kidney disease therapy developer SanReno Therapeutics, enhancing its presence in China's renal disease market. 🚫 Novartis ends pursuit of Cytokinetics, retracting from a potential $10+ billion deal following soaring stock prices and positive treatment data. 💉 Moderna projected $6.7 billion in 2023 Covid-19 vaccine sales, gains U.S. market share against Pfizer, aims for profitability by 2026. 🌟 Bristol Myers Squibb plans to introduce 16 new products by 2030, focusing on diversification and growth through acquisitions. 🙏 Metagenomi files for IPO, signaling growth in gene editing with several preclinical collaborations. 📈 Novo Nordisk's obesity drug Wegovy® shows high patient retention, with 40% still using it after a year, indicating better adherence compared to older treatments. 🧐 Johnson & Johnson tentatively agrees to pay $700 million to settle U.S. state investigations over alleged misleading marketing of its talc-based baby powder.. #Biotech #Biotechnology #Biotechnews #Investment #Partnerships #M&A #Recruiter #Recruitment #LifeScience